P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications
- PMID: 33412103
- PMCID: PMC8096679
- DOI: 10.1016/j.bcp.2021.114406
P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications
Abstract
Purinergic receptors for extracellular nucleotides and nucleosides contribute to a vast array of cellular and tissue functions, including cell proliferation, intracellular and transmembrane ion flux, immunomodulation and thrombosis. In mammals, the purinergic receptor system is composed of G protein-coupled P1 receptors A1, A2A, A2B and A3 for extracellular adenosine, P2X1-7 receptors that are ATP-gated ion channels and G protein-coupled P2Y1,2,4,6,11,12,13 and 14 receptors for extracellular ATP, ADP, UTP, UDP and/or UDP-glucose. Recent studies have implicated specific P2Y receptor subtypes in numerous oncogenic processes, including cancer tumorigenesis, metastasis and chemotherapeutic drug resistance, where G protein-mediated signaling cascades modulate intracellular ion concentrations and activate downstream protein kinases, Src family kinases as well as numerous mitogen-activated protein kinases. We are honored to contribute to this special issue dedicated to the founder of the field of purinergic signaling, Dr. Geoffrey Burnstock, by reviewing the diverse roles of P2Y receptors in the initiation, progression and metastasis of specific cancers with an emphasis on pharmacological and genetic strategies employed to delineate cell-specific and P2Y receptor subtype-specific responses that have been investigated using in vitro and in vivo cancer models. We further highlight bioinformatic and empirical evidence on P2Y receptor expression in human clinical specimens and cover clinical perspectives where P2Y receptor-targeting interventions may have therapeutic relevance to cancer treatment.
Keywords: Cancer; Extracellular nucleotides; Metastasis; P2Y receptors; Proliferation; Purinergic receptors.
Copyright © 2021 Elsevier Inc. All rights reserved.
Conflict of interest statement
7. Conflict of Interest
None to declare
Figures

Similar articles
-
Molecular pharmacology of P2Y receptor subtypes.Biochem Pharmacol. 2021 May;187:114361. doi: 10.1016/j.bcp.2020.114361. Epub 2020 Dec 10. Biochem Pharmacol. 2021. PMID: 33309519 Review.
-
The P2Y/P2X divide: How it began.Biochem Pharmacol. 2021 May;187:114408. doi: 10.1016/j.bcp.2021.114408. Epub 2021 Jan 11. Biochem Pharmacol. 2021. PMID: 33444568 Review.
-
Nucleotides control the excitability of sensory neurons via two P2Y receptors and a bifurcated signaling cascade.Pain. 2011 Aug;152(8):1899-1908. doi: 10.1016/j.pain.2011.04.016. Epub 2011 May 19. Pain. 2011. PMID: 21600693 Free PMC article.
-
G protein-coupled purinergic P2Y receptors in infectious diseases.Pharmacol Ther. 2025 Mar;267:108796. doi: 10.1016/j.pharmthera.2025.108796. Epub 2025 Jan 13. Pharmacol Ther. 2025. PMID: 39814144 Review.
-
Pharmacology and structure of P2Y receptors.Neuropharmacology. 2016 May;104:50-61. doi: 10.1016/j.neuropharm.2015.10.030. Epub 2015 Oct 28. Neuropharmacology. 2016. PMID: 26519900 Review.
Cited by
-
Identification of new head and neck squamous cell carcinoma subtypes and development of a novel score system (PGSscore) based on variations in pathway activity between tumor and adjacent non-tumor samples.Comput Struct Biotechnol J. 2022 Sep 1;20:4786-4805. doi: 10.1016/j.csbj.2022.08.057. eCollection 2022. Comput Struct Biotechnol J. 2022. PMID: 36147682 Free PMC article.
-
The Role of Purinergic Signaling in Heart Transplantation.Front Immunol. 2022 Apr 21;13:826943. doi: 10.3389/fimmu.2022.826943. eCollection 2022. Front Immunol. 2022. PMID: 35529844 Free PMC article. Review.
-
Tail Tales: What We Have Learned About Regeneration from Xenopus Laevis Tadpoles.Int J Mol Sci. 2024 Oct 29;25(21):11597. doi: 10.3390/ijms252111597. Int J Mol Sci. 2024. PMID: 39519148 Free PMC article. Review.
-
Beneficial effect of polyphenols in COVID-19 and the ectopic F1 FO -ATP synthase: Is there a link?J Cell Biochem. 2022 Aug;123(8):1281-1284. doi: 10.1002/jcb.30306. Epub 2022 Jul 15. J Cell Biochem. 2022. PMID: 35838055 Free PMC article.
-
Connexin Hemichannel Activation by S-Nitrosoglutathione Synergizes Strongly with Photodynamic Therapy Potentiating Anti-Tumor Bystander Killing.Cancers (Basel). 2021 Oct 10;13(20):5062. doi: 10.3390/cancers13205062. Cancers (Basel). 2021. PMID: 34680212 Free PMC article.
References
-
- Burnstock G, Historical review: ATP as a neurotransmitter, Trends Pharmacol Sci 27(3) (2006) 166–76. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous